Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 255 (1 March 2008) | doi:10.1038/nbt0308-255a
Another inhaled insulin casualty
Abstract
Novo Nordisk of Bagsvaerd, Denmark, has cancelled development of its phase 3 inhaled insulin program, a move influenced by Pfizer's recent dumping of Exubera (Nat. Biotechnol.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
